CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 549 enrolled
Drug / intervention
Sifrol® (pramipexole dihydrochloride)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00721279
NCT00721279N/ACompleted
CompareCT.gov

Sifrol Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary RLS

Boehringer Ingelheim·observational·Posted Jul 24, 2008·Updated Jun 4, 2014

In Brief

An observational study evaluating Sifrol® (pramipexole dihydrochloride) for Restless Legs Syndrome. Completed, enrolled 549 participants across 127 sites.

Detailed Summary

The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Rating Scale and Global Clinical Impression - Improvement, to evaluate the time to reaching maintenance dose of pramipexole

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome
CountriesAustria
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 24, 2008
Enrollment StartSep 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.9 years ago

Interventions

Sifrol® (pramipexole dihydrochloride)drug